MARKET

MDXG

MDXG

MIMEDX GROUP
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.28
+0.12
+1.08%
Pre Market: 11.57 +0.29 +2.57% 07:44 03/04 EST
OPEN
11.30
PREV CLOSE
11.16
HIGH
11.44
LOW
10.63
VOLUME
951
TURNOVER
--
52 WEEK HIGH
11.44
52 WEEK LOW
2.950
MARKET CAP
1.25B
P/E (TTM)
-16.7832
1D
5D
1M
3M
1Y
5Y
MiMedx to Participate at Upcoming Investor Conferences
GlobeNewswire · 1d ago
The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 2)
Benzinga · 1d ago
MiMedx to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call on March 9
GlobeNewswire · 2d ago
Allogeneic Stem Cells Market Size 2021 By Share, Industry Statistics, Trends Evaluation, Business Challenges and Investment Opportunities Analysis till 2026
Mar 02, 2021 (The Expresswire) -- The Allogeneic Stem Cells Marketresearch report offers the breakdown of the industry by market size, rate of development,...
The Express Wire · 2d ago
Global Skin Replacement and Substitute Market 2020 Key Trends, Sales Growth, Market Value-Chain and Forecast to 2025
Feb 28, 2021 (CDN Newswire via Comtex) -- Global Skin Replacement and Substitute Market 2020 by Company, Type and Application, Forecast to 2025 published by...
CDN Newswire · 4d ago
Should MiMedx Group (NASDAQ:MDXG) Be Disappointed With Their 41% Profit?
Simply Wall St. · 02/25 08:04
Amniotic Membrane Market Analysis Covering Size, Share, Growth, Trends and Upcoming Opportunities
Japan, Japan, Wed, 24 Feb 2021 06:02:33 / Comserve Inc. / -- Amniotic Membrane Market Estimation, Global Share, Industry Outlook, Price Trend, Growth...
Comserve · 02/24 11:03
CEO Who Blamed His Cancer on Short Sellers Gets a Year in Prison
Bloomberg · 02/23 22:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MDXG. Analyze the recent business situations of MIMEDX GROUP through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MDXG stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 130
Institutional Holdings: 45.03M
% Owned: 40.55%
Shares Outstanding: 111.05M
TypeInstitutionsShares
Increased
1
111.32K
New
87
36.00M
Decreased
6
145.44K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-2.37%
Healthcare Equipment & Supplies
-2.63%
Key Executives
Chairman/Independent Director
M. Kathleen Behrens Wilsey
Chief Executive Officer/Director
Timothy Wright
Chief Financial Officer
Peter Carlson
Executive Vice President
Rohit Kashyap
Executive Vice President
Robert Stein
Senior Vice President/Chief Accounting Officer
William Phelan
Senior Vice President/Director of Investor Relations
Jack Howarth
Senior Vice President
Scott Turner
Chief Compliance Officer
Mark Graves
General Counsel/Secretary
William Hulse
Director
Charles Koob
Independent Director
James Bierman
Independent Director
Charles Evans
Independent Director
William Hawkins
Independent Director
K. Todd Newton
Independent Director
Martin Sutter
Independent Director
Neil Yeston
Independent Director
M. Behrens Wilsey
Independent Director
J. Dewberry
No Data
About MDXG
MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Webull offers kinds of MiMedx Group Inc stock information, including NASDAQ:MDXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDXG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDXG stock methods without spending real money on the virtual paper trading platform.